Sensyne Health PLC (AIM:SENS), the clinical artificial intelligence (AI) company, announced two new partnership deals.
The first is a one-year agreement with Exscientia “to leverage the deep learning AI capabilities of the Sensyne platform to study real-world health data,” a statement said.
Exscientia will make an upfront payment for four SENSIGHT subscriptions and a project-based fee, with a 40/60 split between the two. Sensyne will apply its data science expertise to create bespoke data sets from its database of patient records to answer project-specific questions regarding biomarker discovery and targets for new medicines.
SENSIGHT is a clinical AI platform that “provides industrial-scale access to insights from anonymised and de-identified real-world data, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms.”
The second agreement is a strategic partnership with RwHealth, which has signed up for ten SENSIGHT subscription packages. As part of the agreement, RwHealth will also become a SENSIGHT Channel Partner with the right to offer SENSIGHT to its customers.
London headquartered RwHealth, is a healthcare and life sciences data company providing healthcare analytics and information services to UK and international health systems. By deploying advanced artificial intelligence and machine learning technology, RwHealth is able to leverage information at a local, national and global level to create real-time and predictive analytics for healthcare and life sciences.